ArticleThe oncologist2026
Prognostic significance of preoperative thyroid hormone sensitivity status for recurrence in papillary thyroid carcinoma.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe relationship between thyroid hormone sensitivity and the risk of recurrence in patients with papillary thyroid carcinoma (PTC) has not been thoroughly investigated, and it remains unclear whether factors such as thyroid-stimulating hormone suppression efficacy or underlying autoimmune mechanisms mediate this association. The primary objective of the present study was to examine the complex interrelationships among thyroid hormone sensitivity indices and their collective utility as biomarkers for predicting recurrence.
methodsThis study retrospectively analyzed a cohort of 196 patients who underwent initial surgical resection and received a pathological confirmation of PTC between January 2015 and July 2016. Logistic regression analysis was employed to evaluate the potential association of thyroid hormone sensitivity indices-specifically, the thyrotropin index (TSHI) and thyrotroph T4 resistance index (TT4RI)-with PTC recurrence, as well as to assess their predictive utility.
resultsIn patients with PTC, multivariate logistic regression identified both TSHI ≥ 3.6 and TT4RI ≥ 54.2 as independent prognostic factors associated with reduced recurrence risk (TSHI: OR = 0.107, 95% CI: 0.012-0.948, P = .045; TT4RI: OR = 0.158, 95% CI: 0.026-0.529, P = .005). Furthermore, net reclassification improvement (NRI) and integrated discrimination improvement (IDI) analyses revealed that the inclusion of thyroid hormone sensitivity indices significantly enhanced the predictive accuracy for recurrence events (TSHI: NRI = 0.292, 95% CI: -0.001-0.602, P = .064; IDI = 0.032, 95% CI: 0.013-0.051, P = .001; TT4RI: NRI = 0.663, 95% CI: 0.376-0.951, P < .001; IDI = 0.053, 95% CI: 0.025-0.082, P < .001). Finally, receiver operating characteristic curve analysis demonstrated that the combination of TSHI and TT4RI yielded superior predictive performance, with an area under the curve of 0.790 (P < .001), significantly outperforming either index alone.
conclusionIn conclusion, thyroid hormone resistance, indicated by elevated TSHI and TT4RI, represents an independent protective factor against recurrence in PTC. The integration of these indices significantly improves recurrence prediction, with their combination offering superior discriminative ability, highlighting their collective utility as clinically relevant biomarkers for optimizing postoperative surveillance and management strategies in PTC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.